Download PDF
Fortschr Neurol Psychiatr 2004; 72(12): 672-678
DOI: 10.1055/s-2004-830039
Originalarbeit
© Georg Thieme Verlag Stuttgart · New York

Immuntherapie der chronisch inflammatorischen demyelinisierenden Polyneuropathie

Immunotherapy of Chronic Inflammatory Demyelinating PolyneuropathyJ.  D.  Lünemann1, 2 , K.  Prass1 , R.  Zschenderlein1
  • 1Klinik und Poliklinik für Neurologie, Campus Mitte, Charité-Universitätsmedizin Berlin
  • 2National Institutes of Health, National Institute of Neurological Disorders and Stroke, Neuroimmunology Branch, Bethesda, USA
Further Information

Publication History

Publication Date:
11 October 2004 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die chronisch inflammatorische demyelinisierende Polyneuropathie (CIDP) gilt als die häufigste behandelbare chronische Erkrankung des peripheren Nervensystems bei einer Prävalenz von etwa 1 - 2/100 000. Randomisierte und kontrollierte Studien belegen eine vergleichbare therapeutische Wirksamkeit von Glukokortikosteroiden, intravenösen Immunglobulinen und der Plasmapherese. Bei Beobachtungszeiträumen von jeweils weniger als 2 Monaten ist die Effektivität der genannten therapeutischen Optionen in der Akutintervention, nicht jedoch auf vergleichbarem Niveau in der Langzeittherapie gesichert. Die vorliegenden Therapiestudien zeigen zudem übereinstimmend, dass etwa ein Drittel aller Patienten nicht auf die initial gewählte therapeutische Option anspricht. Aufgrund positiver Fallserien in der Literatur können bei unzureichendem Ansprechen der Einsatz von Cyclophosphamid und Cyclosporin A, alternativ Kombinationstherapien erwogen werden. Welcher therapeutische Ansatz initial gewählt wird, hängt wesentlich von der Krankheitsdynamik und der funktionellen Beeinträchtigung des Patienten sowie eventuellen Begleiterkrankungen ab. Die vorliegende Übersicht fasst die derzeitige Studienlage zur Immuntherapie der CIDP zusammen und bewertet vorhandene therapeutische Optionen nach deren Wirksamkeit, Verträglichkeit und Kosten.

Abstract

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired immune-mediated disease of the peripheral nervous system with an estimated prevalence of 1 - 2/100 000. The clinical presentation is heterogeneous, but the most common form causes symmetrical progressive or relapsing weakness affecting proximal and distal muscles. CIDP is among the most treatable peripheral nerve disorders and corticosteroids, plasmapheresis and intravenous immunoglobulin have been shown to be effective in short-term prospective, randomized controlled trials. Data however indicate that approximately one-third of patients do not respond to these treatment modalities, nor do they provide equivalent evidence for a durable clinical response. There is a lack of good quality controlled trials of any other immunosuppressive agent, but cyclophosphamide and cyclosporin may be of value in patients with poor response to first-line modalities. Alternatively, the use of combination therapy may increase the efficacy in unresponsive patients. This review highlights the current status of CIDP treatment trials and discusses the significance of any therapeutic option in terms of efficacy, tolerability and cost-effects.

Literatur

  • 1 Austin J H. Recurrent polyneuropathies and their corticosteroid treatment; with five-year observations of a placebo-controlled case treated with corticotrophin, cortisone, and prednisone.  Brain. 1958;  81 57-192
    PubMedGoogle Scholar
  • 2 Thomas P K, Lascelles R G, Hallpike J F, Hewer R L. Recurrent and chronic relapsing Guillain-Barré polyneuritis.  Brain. 1969;  92 589-606
    PubMedGoogle Scholar
  • 3 Dyck P J, O'Brien P C, Oviatt K F. et al . Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment.  Ann Neurol. 1982;  11 136-141
    CrossrefPubMedGoogle Scholar
  • 4 McLeod J G, Pollard J D, Macaskill P, Mohamed A, Spring P, Khurana V. Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia.  Ann Neurol. 1999;  46 910-913
    CrossrefPubMedGoogle Scholar
  • 5 Lunn M P, Manji H, Choudhary P P, Hughes R A, Thomas P K. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England.  J Neurol Neurosurg Psychiatry. 1999;  66 677-680
    CrossrefPubMedGoogle Scholar
  • 6 Report from an Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force . Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP).  Neurology. 1991;  41 617-618
    PubMedGoogle Scholar
  • 7 Barohn R J, Kissel J T, Warmolts J R, Mendell J R. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria.  Arch Neurol. 1989;  46 878-884
    CrossrefPubMedGoogle Scholar
  • 8 Saperstein D S, Katz J S, Amato A A, Barohn R J. Clinical spectrum of chronic acquired demyelinating polyneuropathies.  Muscle Nerve. 2001;  24 311-324
    CrossrefPubMedGoogle Scholar
  • 9 Koller H, Kieseier B C, Jander S, Hartung H P. [Chronic inflammatory demyelinating polyneuropathy].  Nervenarzt. 2003;  74 320-233
    CrossrefPubMedGoogle Scholar
  • 10 Sander H W, Latov N. Research criteria for defining patients with CIDP.  Neurology. 2003;  60 S8-15
    CrossrefPubMedGoogle Scholar
  • 11 Katz J S, Saperstein D S, Gronseth G, Amato A A, Barohn R J. Distal acquired demyelinating symmetric neuropathy.  Neurology. 2000;  54 615-620
    CrossrefPubMedGoogle Scholar
  • 12 Kieseier B C, Dalakas M C, Hartung H P. Immune mechanisms in chronic inflammatory demyelinating neuropathy.  Neurology. 2002;  59 S7-12
    PubMedGoogle Scholar
  • 13 Dalakas M C. Advances in chronic inflammatory demyelinating polyneuropathy: disease variants and inflammatory response mediators and modifiers.  Curr Opin Neurol. 1999;  12 403-409
    CrossrefPubMedGoogle Scholar
  • 14 Dalakas M C, Engel W K. Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment.  Ann Neurol. 1981;  9 Suppl 134-145
    CrossrefPubMedGoogle Scholar
  • 15 McCombe P A, Pollard J D, McLeod J G. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases.  Brain. 1987;  110 ( Pt 6) 1617-1630
    CrossrefPubMedGoogle Scholar
  • 16 Molenaar D S, Doorn P A van, Vermeulen M. Pulsed high dose dexamethasone treatment in chronic inflammatory demyelinating polyneuropathy: a pilot study.  J Neurol Neurosurg Psychiatry. 1997;  62 388-390
    CrossrefPubMedGoogle Scholar
  • 17 Dyck P J, O'Brien P, Swanson C, Low P, Daube J. Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy.  Neurology. 1985;  35 1173-1176
    CrossrefPubMedGoogle Scholar
  • 18 British and Dutch Multiple Sclerosis Azathioprine Trial Group . Double-masked trial of azathioprine in multiple sclerosis.  Lancet. 1988;  2 179-183
    PubMedGoogle Scholar
  • 19 Hughes R A, Swan A V, Doorn P A van. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2003 CD003280
    Google Scholar
  • 20 Confavreux C, Saddier P, Grimaud J, Moreau T, Adeleine P, Aimard G. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study.  Neurology. 1996;  46 1607-1612
    CrossrefPubMedGoogle Scholar
  • 21 Levy R L, Newkirk R, Ochoa J. Treating chronic relapsing Guillain-Barré-syndrome by plasma exchange.  Lancet. 1979;  2 259-260
    PubMedGoogle Scholar
  • 22 Dyck P J, Daube J, O'Brien P. et al . Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy.  N Engl J Med. 1986;  314 461-465
    CrossrefPubMedGoogle Scholar
  • 23 Hahn A F, Bolton C F, Pillay N. et al . Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study.  Brain. 1996;  119 ( Pt 4) 1055-1066
    CrossrefPubMedGoogle Scholar
  • 24 Hadden R D, Bensa S, Lunn M P, Hughes R A. Immunoadsorption inferior to plasma exchange in a patient with chronic inflammatory demyelinating polyradiculoneuropathy.  J Neurol Neurosurg Psychiatry. 2002;  72 644-646
    CrossrefPubMedGoogle Scholar
  • 25 Choudhary P P, Hughes R A. Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin.  Qjm. 1995;  88 493-502
    PubMedGoogle Scholar
  • 26 Rizvi M A, Vesely S K, George J N. et al . Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome.  Transfusion. 2000;  40 896-901
    CrossrefPubMedGoogle Scholar
  • 27 Hahn A F, Bolton C F, Zochodne D, Feasby T E. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study.  Brain. 1996;  119 ( Pt 4) 1067-1077
    CrossrefPubMedGoogle Scholar
  • 28 Mendell J R, Barohn R J, Freimer M L. et al . Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy.  Neurology. 2001;  56 445-449
    CrossrefPubMedGoogle Scholar
  • 29 Thompson N, Choudhary P, Hughes R A, Quinlivan R M. A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy.  J Neurol. 1996;  243 280-285
    CrossrefPubMedGoogle Scholar
  • 30 Vermeulen M, Doorn P A van, Brand A, Strengers P F, Jennekens F G, Busch H F. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study.  J Neurol Neurosurg Psychiatry. 1993;  56 36-39
    CrossrefPubMedGoogle Scholar
  • 31 Schaik I N van, Winer J B, De Haan R, Vermeulen M. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2002 CD001797
    Google Scholar
  • 32 Dyck P J, Litchy W J, Kratz K M. et al . A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy.  Ann Neurol. 1994;  36 838-845
    CrossrefPubMedGoogle Scholar
  • 33 Brannagan 3rd T H. Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies.  Neurology. 2002;  59 S33-40
    PubMedGoogle Scholar
  • 34 Hughes R, Bensa S, Willison H. et al . Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy.  Ann Neurol. 2001;  50 195-201
    CrossrefPubMedGoogle Scholar
  • 35 Bouchard C, Lacroix C, Plante V. et al . Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy.  Neurology. 1999;  52 498-503
    PubMedGoogle Scholar
  • 36 Good J L, Chehrenama M, Mayer R F, Koski C L. Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy.  Neurology. 1998;  51 1735-1738
    CrossrefPubMedGoogle Scholar
  • 37 Brannagan 3rd T H, Pradhan A, Heiman-Patterson T. et al . High-dose cyclophosphamide without stem-cell rescue for refractory CIDP.  Neurology. 2002;  58 1856-1858
    CrossrefPubMedGoogle Scholar
  • 38 Hodgkinson S J, Pollard J D, McLeod J G. Cyclosporin A in the treatment of chronic demyelinating polyradiculoneuropathy.  J Neurol Neurosurg Psychiatry. 1990;  53 327-330
    CrossrefPubMedGoogle Scholar
  • 39 Kuntzer T, Radziwill A J, Lettry-Trouillat R. et al . Interferon-β1a in chronic inflammatory demyelinating polyneuropathy.  Neurology. 1999;  53 1364-1365
    CrossrefPubMedGoogle Scholar
  • 40 Hadden R D, Sharrack B, Bensa S, Soudain S E, Hughes R A. Randomized trial of interferon β-1a in chronic inflammatory demyelinating polyradiculoneuropathy.  Neurology. 1999;  53 57-61
    CrossrefPubMedGoogle Scholar
  • 41 Vallat J M, Hahn A F, Leger J M. et al . Interferon β-1a as an investigational treatment for CIDP.  Neurology. 2003;  60 S23-28
    CrossrefPubMedGoogle Scholar
  • 42 Gorson K C, Allam G, Simovic D, Ropper A H. Improvement following interferon-α 2A in chronic inflammatory demyelinating polyneuropathy.  Neurology. 1997;  48 777-780
    CrossrefPubMedGoogle Scholar
  • 43 Chin R L, Sherman W H, Sander H W, Hays A P, Latov N. Etanercept (Enbrel) therapy for chronic inflammatory demyelinating polyneuropathy.  J Neurol Sci. 2003;  210 19-21
    CrossrefPubMedGoogle Scholar
  • 44 Vermeulen M, Oers M H van. Successful autologous stem cell transplantation in a patient with chronic inflammatory demyelinating polyneuropathy.  J Neurol Neurosurg Psychiatry. 2002;  72 127-128
    CrossrefPubMedGoogle Scholar

Dr. Jan D. Lünemann

Klinik und Poliklinik für Neurologie, Charité-Universitätsmedizin Berlin, Campus Mitte

Schumannstraße 20/21

10098 Berlin

Email: jan.luenemann@charite.de